Drugs / LETAXABAN
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00677053 | Mar 2008 → Jun 2010 | acute coronary syndrome | Takeda | Completed | No outcome recorded |
| Phase 2 | NCT00641732 | Oct 2007 → Oct 2008 | venous thromboembolism | Takeda | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LETAXABAN | ChEMBL registry synonym — accepted as the source's own label CHEMBL1095032 ↗ |
| Known as | TAK-442 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00641732 ↗ |
| Action | Inhibit | “TAK-442 is an oral inhibitor of activated factor X within the blood coagulation cascade.” NCT00641732 ↗1“Coagulation factor X inhibitor” CHEMBL1095032 ↗ |
| Modality | Small molecule | — CHEMBL1095032 ↗ |
| Route | Oral | “TAK-442 40 mg, tablets, orally, once daily for up to 10 days.” NCT00641732 ↗ |
| Target | F10 | “Coagulation factor X inhibitor” CHEMBL1095032 ↗ |